On multiple courses of alefacept

Journal of the American Academy of Dermatology

Volumn 55, Issue 5, 2006, Pages 916-917

  Leonardi, Craig L ^a   Strober, Bruce E ^b  

^a SAINT LOUIS UNIVERSITY   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; EFALIZUMAB; ETANERCEPT; INFLIXIMAB;

ANALYTIC METHOD; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DRUG EFFICACY; HUMAN; LETTER; PRIORITY JOURNAL; PSORIASIS; RATING SCALE; RISK;

CHRONIC DISEASE; DRUG ADMINISTRATION SCHEDULE; HUMANS; INJECTIONS, INTRAVENOUS; PSORIASIS; RECOMBINANT FUSION PROTEINS; RETREATMENT;

EID: 33749684865     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2006.04.075     Document Type: Letter

References (2)

1. Menter A., Cather J.C., Baker D., Farber H.F., Lebwohl M., and Darif M. The efficacy of multiple courses of alefacept in patents with moderate to severe plaque psoriasis. J Am Acad Dermatol 54 (2006) 61-63
2. Krueger G.G., Papp K.A., Stough D.B., Loven K.H., Gulliver W.P., and Ellis C.N. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 47 (2002) 821-823